A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.
Wrasidlo W, Tsigelny IF, Price DL, Dutta G, Rockenstein E, Schwarz TC, Ledolter K, Bonhaus D, Paulino A, Eleuteri S, Skjevik ÅA, Kouznetsova VL, Spencer B, Desplats P, Gonzalez-Ruelas T, Trejo-Morales M, Overk CR, Winter S, Zhu C, Chesselet MF, Meier D, Moessler H, Konrat R, Masliah E.
Wrasidlo W, et al. Among authors: winter s.
Brain. 2016 Dec;139(Pt 12):3217-3236. doi: 10.1093/brain/aww238. Epub 2016 Sep 27.
Brain. 2016.
PMID: 27679481
Free PMC article.